diethylnitrosamine has been researched along with Fatty Liver, Nonalcoholic in 23 studies
Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.
N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The data reveals potential of saroglitazar for chemoprevention of hepatocellular carcinoma in patients with NAFLD/NASH." | 8.31 | Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. ( Bhoi, B; Giri, SR; Ingale, K; Jain, MR; Kadam, S; Nyska, A; Patel, H; Ranvir, R; Rath, A; Rathod, R; Sharma, A; Trivedi, C, 2023) |
| "Here, we utilized an established model of age- and obesity-associated HCC, the low dose diethylnitrosamine (DEN)/high fat diet (HFD), a regimen promoting liver inflammation and tumorigenesis over a long period of 9 months." | 8.02 | Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin. ( Cabibi, D; Faldyna, M; Frohlich, J; Giallongo, S; Giannone, AG; Kovacovicova, K; Leva, L; Lo Re, O; Oben, JA; Raffaele, M; Vinciguerra, M, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the major causes of hepatocellular carcinoma (HCC)." | 5.72 | Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet. ( Chun, HJ; Kwon, YH; Shim, YJ, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of obesity, is an emerging risk factor for hepatocellular carcinoma (HCC)." | 5.48 | Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis. ( Inoue-Yamauchi, A; Itagaki, H; Oda, H, 2018) |
| "Several animal models of nonalcoholic steatohepatitis have been developed to facilitate its study; however, few fully recapitulate all its clinical features, which include insulin resistance, inflammation, fibrosis, and carcinogenesis." | 5.43 | Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine. ( Abe, Y; Aiura, K; Hibi, T; Itano, O; Kishida, N; Kitagawa, Y; Kitago, M; Masugi, Y; Matsuda, S; Sakamoto, M; Shinoda, M; Yagi, H, 2016) |
| "The data reveals potential of saroglitazar for chemoprevention of hepatocellular carcinoma in patients with NAFLD/NASH." | 4.31 | Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. ( Bhoi, B; Giri, SR; Ingale, K; Jain, MR; Kadam, S; Nyska, A; Patel, H; Ranvir, R; Rath, A; Rathod, R; Sharma, A; Trivedi, C, 2023) |
| "Here, we utilized an established model of age- and obesity-associated HCC, the low dose diethylnitrosamine (DEN)/high fat diet (HFD), a regimen promoting liver inflammation and tumorigenesis over a long period of 9 months." | 4.02 | Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin. ( Cabibi, D; Faldyna, M; Frohlich, J; Giallongo, S; Giannone, AG; Kovacovicova, K; Leva, L; Lo Re, O; Oben, JA; Raffaele, M; Vinciguerra, M, 2021) |
| "These data indicate that dietary sugar intake contributes to liver tumor burden independent of excess adiposity or insulin resistance in mice treated with diethylnitrosamine." | 3.81 | Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. ( Breen, DS; Byrne, FL; Caldwell, SH; Chow, JD; Healy, ME; Hoehn, KL; Lackner, C; Leitinger, N; Li, C, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the major causes of hepatocellular carcinoma (HCC)." | 1.72 | Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet. ( Chun, HJ; Kwon, YH; Shim, YJ, 2022) |
| "The role of TTP in nonalcoholic steatohepatitis and HCC development was further examined through in vivo/vitro approaches using liver-specific TTP knockout mice and a panel of hepatic cancer cells." | 1.62 | Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy. ( Bejuy, O; Berthou, F; Blackshear, PJ; Colin, DJ; Correia de Sousa, M; De Vito, C; Dolicka, D; Foti, M; Fournier, M; Gjorgjieva, M; Maeder, C; Rubbia-Brandt, L; Sobolewski, C, 2021) |
| "Hepatocellular carcinoma in nonalcoholic steatohepatitis is caused by the complex factors of inflammation, fibrosis and microbiomes." | 1.62 | Microbiome, fibrosis and tumor networks in a non-alcoholic steatohepatitis model of a choline-deficient high-fat diet using diethylnitrosamine. ( Fujishiro, M; Honda, T; Ishigami, M; Ishizu, Y; Ito, T; Kato, A; Kawashima, H; Kuzuya, T; Ma, L; Nakamura, M; Tsuji, NM; Yamamoto, K; Yokoyama, S, 2021) |
| "In the NAFLD pigs, hepatic histology of nonalcoholic steatohepatitis (NASH) was observed at 36 weeks, and HCC developed at 60 weeks." | 1.51 | Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study. ( Aizawa, N; Hatano, E; Iguchi, K; Iijima, H; Ikegawa, M; Kawaguchi, H; Nakamura, N; Nishiguchi, S; Ohtsu, I; Okuda, Y; Sakurai, T; Sato, M; Seo, S; Taura, K; Tomono, T; Uemoto, S; Wada, S, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of obesity, is an emerging risk factor for hepatocellular carcinoma (HCC)." | 1.48 | Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis. ( Inoue-Yamauchi, A; Itagaki, H; Oda, H, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) encompasses a broad spectrum of conditions, ranging from non-progressive bland steatosis to hepatocarcinoma." | 1.46 | Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma. ( Bischetti, S; Casagrande, V; Federici, M; Mauriello, A; Mavilio, M; Menghini, R, 2017) |
| "Without treatment, NAFLD may progress to hepatocellular carcinoma (HCC), a cancer with a high mortality rate." | 1.43 | Dietary Broccoli Lessens Development of Fatty Liver and Liver Cancer in Mice Given Diethylnitrosamine and Fed a Western or Control Diet. ( Chen, YJ; Jeffery, EH; Wallig, MA, 2016) |
| "Several animal models of nonalcoholic steatohepatitis have been developed to facilitate its study; however, few fully recapitulate all its clinical features, which include insulin resistance, inflammation, fibrosis, and carcinogenesis." | 1.43 | Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine. ( Abe, Y; Aiura, K; Hibi, T; Itano, O; Kishida, N; Kitagawa, Y; Kitago, M; Masugi, Y; Matsuda, S; Sakamoto, M; Shinoda, M; Yagi, H, 2016) |
| "Many animal models of nonalcoholic steatohepatitis have been reported." | 1.43 | A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis. ( Ejima, C; Ishizaki, S; Kuroda, H, 2016) |
| "Sorafenib treatment restored mitochondrial function and reduced collagen deposition by nearly 63% compared to the NASH group." | 1.42 | Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. ( Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP, 2015) |
| "Liver cancer is a major health-care concern and its oncogenic mechanisms are still largely unclear." | 1.42 | Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation. ( Eguchi, A; Feldstein, AE; Font-Burgada, J; Johnson, CD; Karin, M; Povero, D; Wree, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (69.57) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Chun, HJ | 1 |
| Shim, YJ | 1 |
| Kwon, YH | 1 |
| Márquez-Quiroga, LV | 1 |
| Arellanes-Robledo, J | 1 |
| Vásquez-Garzón, VR | 1 |
| Villa-Treviño, S | 1 |
| Muriel, P | 1 |
| Giri, SR | 1 |
| Bhoi, B | 1 |
| Trivedi, C | 1 |
| Rath, A | 1 |
| Rathod, R | 1 |
| Sharma, A | 1 |
| Ranvir, R | 1 |
| Kadam, S | 1 |
| Ingale, K | 1 |
| Patel, H | 1 |
| Nyska, A | 1 |
| Jain, MR | 1 |
| Dolicka, D | 1 |
| Sobolewski, C | 1 |
| Gjorgjieva, M | 1 |
| Correia de Sousa, M | 1 |
| Berthou, F | 1 |
| De Vito, C | 1 |
| Colin, DJ | 1 |
| Bejuy, O | 1 |
| Fournier, M | 1 |
| Maeder, C | 1 |
| Blackshear, PJ | 1 |
| Rubbia-Brandt, L | 1 |
| Foti, M | 1 |
| Haberl, EM | 2 |
| Pohl, R | 2 |
| Rein-Fischboeck, L | 2 |
| Höring, M | 1 |
| Krautbauer, S | 1 |
| Liebisch, G | 1 |
| Buechler, C | 2 |
| Yamamoto, K | 1 |
| Honda, T | 1 |
| Yokoyama, S | 1 |
| Ma, L | 1 |
| Kato, A | 1 |
| Ito, T | 1 |
| Ishizu, Y | 1 |
| Kuzuya, T | 1 |
| Nakamura, M | 1 |
| Kawashima, H | 1 |
| Ishigami, M | 1 |
| Tsuji, NM | 1 |
| Fujishiro, M | 1 |
| Raffaele, M | 1 |
| Kovacovicova, K | 1 |
| Frohlich, J | 1 |
| Lo Re, O | 1 |
| Giallongo, S | 1 |
| Oben, JA | 1 |
| Faldyna, M | 1 |
| Leva, L | 1 |
| Giannone, AG | 1 |
| Cabibi, D | 1 |
| Vinciguerra, M | 1 |
| Casagrande, V | 1 |
| Mauriello, A | 1 |
| Bischetti, S | 1 |
| Mavilio, M | 1 |
| Federici, M | 1 |
| Menghini, R | 1 |
| Ploeger, JM | 1 |
| Manivel, JC | 1 |
| Boatner, LN | 1 |
| Mashek, DG | 1 |
| Inoue-Yamauchi, A | 1 |
| Itagaki, H | 1 |
| Oda, H | 1 |
| Reebye, V | 1 |
| Huang, KW | 1 |
| Lin, V | 1 |
| Jarvis, S | 1 |
| Cutilas, P | 1 |
| Dorman, S | 1 |
| Ciriello, S | 1 |
| Andrikakou, P | 1 |
| Voutila, J | 1 |
| Saetrom, P | 1 |
| Mintz, PJ | 1 |
| Reccia, I | 1 |
| Rossi, JJ | 1 |
| Huber, H | 1 |
| Habib, R | 1 |
| Kostomitsopoulos, N | 1 |
| Blakey, DC | 1 |
| Habib, NA | 1 |
| Feder, S | 1 |
| Sinal, CJ | 1 |
| Sylvester Darvin, S | 1 |
| Toppo, E | 1 |
| Esakkimuthu, S | 1 |
| Ajeesh Krishna, TP | 1 |
| Ceasar, SA | 1 |
| Stalin, A | 1 |
| Balakrishna, K | 1 |
| Muniappan, N | 1 |
| Pazhanivel, N | 1 |
| Mahaprabhu, R | 1 |
| Paulraj, MG | 1 |
| Pandikumar, P | 1 |
| Ignacimuthu, S | 1 |
| Al-Dhabi, NA | 1 |
| Lee, SR | 1 |
| Lee, YH | 1 |
| Yang, H | 1 |
| Lee, HW | 1 |
| Lee, GS | 1 |
| An, BS | 1 |
| Jeung, EB | 1 |
| Park, BK | 1 |
| Hong, EJ | 1 |
| Nakamura, N | 1 |
| Hatano, E | 1 |
| Iguchi, K | 1 |
| Sato, M | 1 |
| Kawaguchi, H | 1 |
| Ohtsu, I | 1 |
| Sakurai, T | 1 |
| Aizawa, N | 1 |
| Iijima, H | 1 |
| Nishiguchi, S | 1 |
| Tomono, T | 1 |
| Okuda, Y | 1 |
| Wada, S | 1 |
| Seo, S | 1 |
| Taura, K | 1 |
| Uemoto, S | 1 |
| Ikegawa, M | 1 |
| Kessler, SM | 1 |
| Simon, Y | 1 |
| Gemperlein, K | 1 |
| Gianmoena, K | 1 |
| Cadenas, C | 1 |
| Zimmer, V | 1 |
| Pokorny, J | 1 |
| Barghash, A | 1 |
| Helms, V | 1 |
| van Rooijen, N | 1 |
| Bohle, RM | 1 |
| Lammert, F | 1 |
| Hengstler, JG | 1 |
| Mueller, R | 1 |
| Haybaeck, J | 1 |
| Kiemer, AK | 1 |
| Healy, ME | 1 |
| Chow, JD | 1 |
| Byrne, FL | 1 |
| Breen, DS | 1 |
| Leitinger, N | 1 |
| Li, C | 1 |
| Lackner, C | 1 |
| Caldwell, SH | 1 |
| Hoehn, KL | 1 |
| Stefano, JT | 1 |
| Pereira, IV | 1 |
| Torres, MM | 1 |
| Bida, PM | 1 |
| Coelho, AM | 1 |
| Xerfan, MP | 1 |
| Cogliati, B | 1 |
| Barbeiro, DF | 1 |
| Mazo, DF | 1 |
| Kubrusly, MS | 1 |
| D'Albuquerque, LA | 1 |
| Souza, HP | 1 |
| Carrilho, FJ | 1 |
| Oliveira, CP | 1 |
| Wree, A | 1 |
| Johnson, CD | 1 |
| Font-Burgada, J | 1 |
| Eguchi, A | 1 |
| Povero, D | 1 |
| Karin, M | 1 |
| Feldstein, AE | 1 |
| Chen, YJ | 1 |
| Wallig, MA | 1 |
| Jeffery, EH | 1 |
| Miyazaki, T | 1 |
| Shirakami, Y | 1 |
| Kubota, M | 1 |
| Ideta, T | 1 |
| Kochi, T | 1 |
| Sakai, H | 1 |
| Tanaka, T | 1 |
| Moriwaki, H | 1 |
| Shimizu, M | 1 |
| Kishida, N | 1 |
| Matsuda, S | 1 |
| Itano, O | 1 |
| Shinoda, M | 1 |
| Kitago, M | 1 |
| Yagi, H | 1 |
| Abe, Y | 1 |
| Hibi, T | 1 |
| Masugi, Y | 1 |
| Aiura, K | 1 |
| Sakamoto, M | 1 |
| Kitagawa, Y | 1 |
| Ejima, C | 1 |
| Kuroda, H | 1 |
| Ishizaki, S | 1 |
1 review available for diethylnitrosamine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; Diet, High-Fat; Diethylnitrosamine; Diseas | 2022 |
22 other studies available for diethylnitrosamine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet.
Topics: Amino Acids; Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cholesterol; Cholesterol, Dietary; | 2022 |
Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.
Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Choline; Diet, High-Fat; Diethylnitrosamine; Diseas | 2023 |
Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Datasets as Topic; Diethylnitr | 2021 |
Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.
Topics: alpha-Fetoproteins; Animal Feed; Animals; Carcinoma, Hepatocellular; Ceramides; Choline; Choline Def | 2020 |
Microbiome, fibrosis and tumor networks in a non-alcoholic steatohepatitis model of a choline-deficient high-fat diet using diethylnitrosamine.
Topics: Alkylating Agents; Animals; Carcinogenesis; Carcinoma, Hepatocellular; Choline Deficiency; Cyclin-De | 2021 |
Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin.
Topics: Aging; Animals; Dasatinib; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Disease Progr | 2021 |
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.
Topics: ADAM17 Protein; Albumins; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinogenesis; Ca | 2017 |
Caloric Restriction Prevents Carcinogen-Initiated Liver Tumorigenesis in Mice.
Topics: Animals; Caloric Restriction; Carcinogenesis; Carcinogens; Chemical and Drug Induced Liver Injury; D | 2017 |
Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis.
Topics: Animals; Carcinogenesis; Carcinogens; Carcinoma, Hepatocellular; Diet, High-Fat; Diethylnitrosamine; | 2018 |
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Topics: Animals; CCAAT-Enhancer-Binding Proteins; Diethylnitrosamine; End Stage Liver Disease; Gene Expressi | 2018 |
Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
Topics: Adiponectin; Animals; Body Composition; Chemokines; Choline Deficiency; Diethylnitrosamine; Gene Exp | 2018 |
Hepatoprotective effect of bisbenzylisoquinoline alkaloid tiliamosine from Tiliacora racemosa in high-fat diet/diethylnitrosamine-induced non-alcoholic steatohepatitis.
Topics: Alkaloids; Animals; Benzylisoquinolines; Cell Line, Tumor; Cell Survival; Diet, High-Fat; Diethylnit | 2018 |
Sex hormone-binding globulin suppresses NAFLD-triggered hepatocarcinogenesis after menopause.
Topics: Acetyl-CoA Carboxylase; Animals; Carcinogenesis; Carcinoma, Hepatocellular; Diet, High-Fat; Diethyln | 2019 |
Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Topics: Acute-Phase Proteins; Adolescent; Adult; Aged; Animals; Biomarkers; Blood Proteins; Carcinogens; Car | 2019 |
Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Choline; Diet; Diethylnitrosamine; Disease M | 2014 |
Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine.
Topics: Adipokines; Adiposity; Animals; Carcinogens; Diet, Ketogenic; Diet, Western; Dietary Carbohydrates; | 2015 |
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collag | 2015 |
Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.
Topics: Animals; BH3 Interacting Domain Death Agonist Protein; Carbon Tetrachloride; Cell Proliferation; Cel | 2015 |
Dietary Broccoli Lessens Development of Fatty Liver and Liver Cancer in Mice Given Diethylnitrosamine and Fed a Western or Control Diet.
Topics: Alanine Transaminase; Animals; Brassica; Carcinoma, Hepatocellular; Diet, Western; Diethylnitrosamin | 2016 |
Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice.
Topics: Alginates; Animals; Cell Transformation, Neoplastic; Diabetes Mellitus, Experimental; Diethylnitrosa | 2016 |
Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine.
Topics: Animals; Biomarkers; Body Weight; Carcinoma, Hepatocellular; Choline Deficiency; Diet, High-Fat; Die | 2016 |
A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis.
Topics: Animals; Cholesterol; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrosis; Insulin | 2016 |